Figure 5From: Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acidInhibition of the LPA3 receptor using siRNA knockdown or LPA3 antagonists reduces viability of MeWo melanoma cells. (A) MeWo cells were plated in 96-wells and transfected with the indicated siRNAs for 24 h prior to the assessment of viability. The control, siNegative (non-targeting siRNA), was normalized to 100%. *p < 0.05 and **p < 0.01 vs. siNegative control. (B) The agonist, VPC31144(S) 5 μM was added to either MeWo cells or OVCAR-3 cells in 96-well plates in serum-free medium and compared to control, serum-free medium alone. *p < 0.05 comparing agonist to untreated in each group. (C) MeWo or OVCAR-3 cells were plated in 96-wells prior to transfection with the indicated siRNA conditions. The LPA1/3 antagonist, VPC32183 (20 μM) was added to the cells and viability was assessed. *p < 0.05, ***p < 0.001 comparing treated vs. untreated in each transfection condition. (D) MeWo cells were plated in 96-wells prior to transfection with the indicated siRNAs for 24 h and treatment with Thio-ccPA 18:1 (50 μM) in serum-containing medium. Cell viability was assessed and the siNegative control was normalized to 100%. ***p < 0.001 comparing treated vs. untreated in each transfection condition.Back to article page